CA-NETAPP
26.6.2024 14:01:30 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) has received a AAA rating from SE Labs, an independently-owned and run testing company that assesses security products and services. SE Labs validated the protection effectiveness of NetApp ARP/AI with 99 percent recall—a metric that measures malware detection rates—for ransomware attacks, while noting the absence of false positives.
When responding to ransomware attacks, seconds can make the difference between ensuring continuity and a massive business disruption. Organizations need fast, automated, and accurate detection and response capabilities built into their primary storage systems to minimize the damage done by lost production data and downtime. NetApp ARP/AI, with its AI-powered ransomware detection capability, addresses this gap by providing real-time detection and response to minimize the impact of cybersecurity threats.
SE Labs rigorously tested NetApp ARP/AI against hundreds of known ransomware variants with impressive results. NetApp ARP/AI demonstrated 99 percent detection of advanced ransomware attacks. NetApp ARP/AI also achieved 100 percent detection of legitimate files without flagging any false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue.
Ensuring data is secure against internal and external threats is a critical part of making data infrastructure intelligent which then empowers customers to turn disruption into opportunity. This validation of NetApp’s AI-powered ransomware detection capabilities underscores how NetApp is staying at the forefront of AI innovation by both enabling AI adoption and applying AI to data services. NetApp’s newly released more powerful, all-flash storage systems help enterprises leverage their data to drive AI workloads, built on NetApp’s secure storage infrastructure.
"NetApp has passed a significant milestone in the fight against ransomware as the first and only storage vendor to offer AI-driven on-box ransomware detection with externally validated top-notch protection effectiveness,” said Dr. Arun Gururajan, Vice President, Research & Data Science at NetApp. “Ransomware detection methodologies that rely only on backup data are too slow to effectively mitigate the risks businesses face from cybersecurity threats. NetApp ARP/AI hardens enterprise storage by providing robust, built-in detection capabilities that can respond to ransomware threats in real time. The AAA rating we achieved from SE Labs is the result of our commitment to innovation in intelligent data infrastructure and our drive to find new ways to make NetApp the most secure storage on the planet.”
By embedding ransomware detection in storage, NetApp ARP/AI helps customers improve their cyber resilience while reducing the operational burden and skills required to maintain their intelligent data infrastructure. NetApp ARP/AI’s detection technology continuously adapts and evolves as new ransomware variants are discovered. This continuous retraining on the latest ransomware strains ensures that NetApp ARP/AI remains at the forefront of protection effectiveness, offering organizations a future-proof defense against the dynamic ransomware landscape.
To see the full results of the tests, read the SE Labs Report.
NetApp ARP/AI is currently in tech preview. Customers can request to participate in the tech preview by reaching out to their NetApp sales representative.
Additional Resources
- NetApp, the First and Leading AI-Powered Autonomous Ransomware Protection Native to Storage Achieves Remarkable AAA Rating and 99% Detection Accuracy and 100% Legitimate Accuracy in SE Labs Validation Testing
- Protect, Detect, Recover; Guaranteed
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626446291/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom